CHPF

CHPF is a chondroitin sulfate glycosyltransferase that drives biosynthesis of chondroitin sulfate chains by assembling into heterodimeric polymerizing complexes [PMID:bio_10.1101_2025.03.21.644485, PMID:33390789]. Cryo-EM and in vitro reconstitution of the CHSY3-CHPF complex established that CHPF pairs with the bifunctional active subunits CHSY1 or CHSY3 (forming CHSY1-CHPF, CHSY1-CHPF2, CHSY3-CHPF, and CHSY3-CHPF2), where CHPF chiefly stabilizes the enzymatically active CHSY partner and chain elongation proceeds by a non-processive, disruptive mechanism [PMID:bio_10.1101_2025.03.21.644485]; CRISPR knockout of CHPF (ChSy-2) confirms its requirement for cellular chondroitin sulfate output, reducing placental-type CS-A (PMID:33390789). In cancer, CHPF-mediated CS modification of cell-surface and matrix proteoglycans reshapes signaling: it adds CS chains to syndecan-4 to promote G-CSF accumulation, myeloid-derived suppressor cell expansion, and breast tumor progression (PMID:33791155), and modifies the matrix proteoglycan decorin to alter its surface distribution and tune TGF-β signaling in hepatocellular carcinoma (PMID:33809195). Across additional tumor types CHPF is recurrently linked to proliferative and survival signaling through MAPK and AKT pathways and to ubiquitination-dependent control of cell-cycle and signaling effectors (PMID:30826152, PMID:37492722). CHPF physically interacts with MAD1L1 in glioma and is transcriptionally driven by HNF4A (PMID:37851364), and is post-transcriptionally repressed by extracellular-vesicle–delivered miR-150-3p in endothelial cells (PMID:37156185).

1. 2019 Low

   Established a functional link between CHPF and a defined oncogenic signaling axis, moving CHPF from a glycosyltransferase to a cancer-relevant regulator.

   Evidence Lentiviral CHPF knockdown with MAPK pathway readouts and xenografts in lung adenocarcinoma

   PMID:30826152

   Open questions at the time

   • Pathway placement inferred from phospho/expression changes, not direct mechanism
   • No connection drawn to CHPF glycosyltransferase activity
   • Single lab
2. 2020 Low

   Tested whether CHPF drives proliferation through a specific cell-cycle effector, addressing how its expression promotes malignancy.

   Evidence CHPF gain/loss with RNA-seq/IPA and CDK1 knockdown rescue epistasis in melanoma plus xenografts

   PMID:32612115

   Open questions at the time

   • CDK1 link from transcriptomics, no direct biochemical mechanism
   • How CHPF enzymatic function connects to CDK1 unresolved
3. 2021 Medium

   Identified specific proteoglycan substrates of CHPF and connected CS modification to extracellular signaling, defining a mechanism beyond bulk CS synthesis.

   Evidence shRNA knockdown with substrate (SDC4) co-localization and tumor microenvironment readouts in breast cancer; overexpression/knockdown linking CHPF-modified decorin to TGF-β in HCC

   PMID:33791155 PMID:33809195

   Open questions at the time

   • Substrate modification shown by co-localization/correlation, not biochemical reconstitution
   • Opposite phenotypic directions across tumor types not mechanistically reconciled
4. 2021 Medium

   Demonstrated that CHPF is required for cellular chondroitin sulfate production and that loss of CS output is anti-tumorigenic, tying enzymatic function to phenotype.

   Evidence CRISPR/Cas9 knockout of CHPF (ChSy-2) in JEG3 cells with direct pl-CSA measurement and in vitro/in vivo functional assays

   PMID:33390789

   Open questions at the time

   • Does not resolve which CS-modified substrates mediate the phenotype
   • Single cell-line context
5. 2021 Medium

   Placed CHPF upstream of ubiquitination-controlled cell-cycle regulators, proposing a route from CHPF to proliferation control.

   Evidence shRNA knockdown with E2F1 knockdown rescue epistasis and UBE2T-mediated ubiquitination assessment in gastric cancer

   PMID:34564711

   Open questions at the time

   • Mechanism inferred via epistasis, not reconstituted
   • Link between CHPF glycosyltransferase activity and ubiquitination machinery unexplained
6. 2022 Low

   Extended CHPF's signaling reach to the AKT pathway via control of an E3 substrate-recognition factor's ubiquitination.

   Evidence Overexpression/knockdown with SKP2 ubiquitination and AKT pathway blotting in osteosarcoma plus xenografts

   PMID:37492722

   Open questions at the time

   • No reconstitution of SKP2 ubiquitination control by CHPF
   • Single lab
7. 2023 Medium

   Provided the first direct physical interactor and transcriptional regulator of CHPF, beginning to define its protein-interaction and regulatory context.

   Evidence Reciprocal Co-IP, GST pulldown, LC-MS/MS for MAD1L1 interaction and ChIP-PCR for HNF4A binding in glioma

   PMID:37851364

   Open questions at the time

   • Functional consequence of CHPF-MAD1L1 interaction not defined
   • Interaction not linked to CHPF catalytic role
8. 2023 Medium

   Established CHPF as a direct target of microRNA regulation controlling endothelial angiogenic behavior.

   Evidence Luciferase reporter validation of miR-150-3p binding to CHPF with functional endothelial assays

   PMID:37156185

   Open questions at the time

   • Downstream effectors of CHPF in endothelial cells not defined
   • Single context (hypoxic trophoblast EVs)
9. 2024 Low

   Added further ubiquitination-dependent and inflammasome-linked downstream axes plus an additional upstream transcription factor in colorectal cancer.

   Evidence Knockdown/overexpression with SMAD9/ASB2 ubiquitination epistasis and MAPK/NLRP3 phospho-protein readouts; NFIC regulation in colorectal cancer

   PMID:38267731 PMID:38591191

   Open questions at the time

   • Pathways placed by expression/phospho changes without reconstitution
   • NFIC-CHPF promoter binding not directly demonstrated
10. 2025 High

    Resolved the molecular architecture and catalytic logic of CHPF, defining it as a stabilizing subunit of CHSY-containing chondroitin sulfate polymerase complexes.

    Evidence Cryo-EM structure of CHSY3-CHPF, in vitro glycosylation with synthetic fluorescent substrates, mutagenesis, and in cellulo complementation (preprint)

    PMID:bio_10.1101_2025.03.21.644485

    Open questions at the time

    • How complex composition selects specific proteoglycan substrates unknown
    • Structural basis for non-processive disruptive mechanism not fully detailed

• How CHPF's biochemically defined CS-polymerizing activity mechanistically connects to its many reported ubiquitination and signaling outputs across cancers remains unresolved.
• No reconstitution linking CS modification of specific substrates to MAPK/AKT/TGF-β phenotypes
• Whether non-enzymatic CHPF functions explain protein-interaction effects (e.g., MAD1L1) is untested